The ADC field faces a future challenge: as TOPA1 payload-based ADCs become standard treatments, patients will develop resistance. This will render other TOPA1-based ADCs ineffective for those patients, creating a significant market need and R&D focus on developing entirely new classes of therapeutic payloads to overcome this mechanism.

The current ADC landscape is saturated with similar drugs using topo-isomerase-1 inhibitors. This creates a market opportunity and an ethical imperative to develop new payloads with different mechanisms of action to treat patients who will inevitably develop resistance to the current generation of therapies.

A key innovation in Antibody-Drug Conjugates (ADCs) is the 'tandem cleave' linker. This technology requires two separate events—one in the tumor microenvironment and another after internalization—to release the payload, improving stability and reducing systemic toxicity.

To mitigate the severe toxicity of promising pan-RAS inhibitors, companies are adopting antibody-drug conjugate (ADC) technology. This marks a strategic expansion for ADCs, moving beyond traditional cytotoxic chemotherapy payloads to delivering highly specific targeted therapies, aiming to improve the therapeutic window of potent new drug classes.

Experts question the efficacy of sequencing ADCs like EV (Nectin-4 target) and DV (HER2 target) because they share the same MMAE chemo payload. Since resistance is often tied to the payload, not the target antibody, switching targets may not overcome resistance, though anecdotal responses have been observed.

Navigator Medicines challenges the industry's bias for novel mechanisms. Their strategy is to take a well-validated target (anti-TNF) and innovate by solving its known problems—like immune response, formulation, and dosing—to create a best-in-class therapy. This represents a de-risked approach to innovation.

The current pipeline for antibody-drug conjugates (ADCs) in bladder cancer focuses on incremental changes. These include creating "me-too" drugs similar to Enfortumab Vedotin, or swapping its toxic payload for a different one while keeping the same Nectin-4 target. No immediate practice-changing breakthroughs are expected.

A next-generation Nectin-4 targeting ADC demonstrated a 33% response rate in patients who had already progressed on enfortumab vedotin (EV). This indicates that Nectin-4 remains a viable therapeutic target post-EV, suggesting resistance is not always due to target loss.

Novartis is entering the crowded Antibody-Drug Conjugate (ADC) space late, but its Murex acquisition suggests a strategy to bypass competitors by focusing on innovative payloads (NMT inhibitors) rather than iterating on existing linkers and targets. This is a bet on the next wave of ADC technology.